EW

Edwards Lifesciences
D

EW

Arincen78/100B

Edwards Lifesciences income statement 1999–2026

6.67B USD over the last twelve months, and 6.07B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
6.67B6.07B5.44B5.01B5.38B5.23B4.39B4.35B3.72B3.44B2.96B
Revenue growth
+13.44%+11.55%+8.57%-6.92%+2.86%+19.29%+0.88%+16.79%+8.37%+15.91%+18.85%
Cost of revenue
1.46B1.33B1.12B1.04B1.17B1.23B1.10B1.16B922.10M882.90M805.80M
Gross profit
5.22B4.74B4.32B3.97B4.22B4.01B3.29B3.19B2.80B2.55B2.16B
Gross margin
78.13%78.13%79.46%79.30%78.31%76.57%74.94%73.43%75.23%74.30%72.81%
Research and development
1.09B1.08B1.05B962.90M945.20M903.10M760.70M752.70M622.20M552.60M442.20M
Selling, general and administrative
2.25B2.09B1.79B1.58B1.57B1.49B1.23B1.24B1.09B989.70M900.20M
Operating expenses
3.55B3.10B2.94B2.55B2.51B2.40B1.99B1.99B1.71B1.54B1.34B
1.66B1.64B1.38B1.43B1.70B1.61B1.30B1.20B1.09B1.01B815.50M
Operating income growth
+6.19%+18.68%-3.41%-16.16%+5.71%+24.26%+8.19%+9.67%+8.14%+23.86%+41.60%
Operating margin
24.87%26.97%25.35%28.49%31.63%30.78%29.55%27.55%29.34%29.40%27.52%
Interest income
135.90M148.40M120.30M67.20M35.50M17.40M23.40M32.20M32.00M20.30M10.80M
Interest expense
——19.80M17.60M26.20M24.80M22.20M27.30M33.40M23.20M18.00M
Other non-operating income
-271.20M-363.30M169.40M-54.90M65.00M91.60M-379.30M-31.40M-330.90M24.80M-77.60M
Pretax income
1.43B1.27B1.55B1.37B1.77B1.70B916.70M1.17B761.40M1.03B737.90M
Income tax
444.70M216.90M152.10M152.40M245.50M198.90M93.30M119.60M39.20M451.30M168.40M
Effective tax rate
31.05%17.04%9.82%11.10%13.89%11.69%10.18%10.25%5.15%43.61%22.82%
1.02B1.07B4.17B1.40B1.52B1.50B823.40M1.05B722.20M622.10M569.50M
Net income growth
-25.34%-74.29%+197.68%-7.85%+1.25%+82.55%-21.35%+44.96%+16.09%+9.24%+15.07%
Net margin
15.30%17.69%76.75%27.99%28.28%28.73%18.77%24.08%19.40%18.11%19.22%
Basic shares
578.08M584.80M597.70M606.70M619.00M623.30M622.60M624.90M627.60M632.70M639.00M
Diluted shares
579.43M585.80M599.30M609.40M624.20M631.20M631.90M636.60M640.80M647.70M653.40M
Change in diluted shares
-1.45%-2.25%-1.66%-2.37%-1.11%-0.11%-0.74%-0.66%-1.07%-0.87%-1.13%
EPS (basic)
1.771.846.982.312.462.411.321.681.150.980.89
EPS (diluted)
1.771.836.972.302.442.381.301.641.130.960.87
EPS growth
-23.71%-73.74%+203.04%-5.74%+2.52%+83.08%-20.73%+45.13%+17.71%+10.34%+16.00%
EBITDA
1.60B1.43B1.72B1.53B1.93B1.86B1.05B1.28B872.20M1.14B827.10M
EBITDA margin
24.02%23.56%31.68%30.64%35.92%35.58%23.85%29.51%23.43%33.18%27.91%
EBIT
1.43B1.27B1.57B1.39B1.79B1.73B938.90M1.19B794.80M1.06B755.90M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Edwards Lifesciences's income statement

Source: Financial Modeling Prep